bright ideas
made brilliant

We take current therapies and make them better.

at Propella

We advance promising therapies with high efficiency and reduced risk due to the fact that all of our product candidates are developed using proven active ingredients. Our new and patented best-in-class products appeal to both patients and physicians.

Every day we are earnestly pushing ahead.

our approach

We start with good, and rapidly and intelligently move to great.
> learn more

our pipeline

Discover the potential that is currently underway at Propella
> learn more

latest news

Propella Therapeutics, Inc. presented the results of its recently completed Phase 2 double-blind clinical trial (which examined the tolerability, safety and effects of CGS-200-5 (5% capsaicin topical liquid) on osteoarthritis knee pain) at the 14th Annual Pain Therapeutics Summit on September 21-22, 2020.

Propella Therapeutics, Inc. will present "Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model" at the American Society of Clinical Oncology Genitourinary Cancers Symposium on February 11, 2021.

Propella Therapeutics Inc., a leader in the development of innovative best-in-class prescription products, today announced the issuance of a U.S. patent for a new drug treatment for metastatic prostate cancer. The patent covers new molecules that are designed to provide significant advantages over the current standard of care.

“Propella” comes from the combination of “propel”, to drive, push and cause forward or upward motion, and “Capella”, a first magnitude star used in navigation. Capella consists of a primary pair of stars, which enhance, illuminate and strengthen each other, ultimately appearing as one.

Investing

bright ideas made brilliant

at Propella

our approach

our pipeline

latest news

bright ideas
made brilliant